Trevi Therapeutics, Inc. (TRVI) — AI News Sentiment & Analysis

Continued progress in Phase 3 OCEAN-1 and OCEAN-2 trials, Phase 2b LAKE trial, and the FDA meeting for non-IPF ILD chronic cough, leading to future data readouts and potential regulatory approvals for Haduvio. (Timing: Topline data for OCEAN-2 in H2 2027, LAKE in H2 2027, OCEAN-1 in H1 2028. Sample size re-estimation for LAKE in Q4 2026.)

The closing of the underwritten public offering, including the full exercise of the underwriters' option, confirms the company's ability to secure substantial funding. This directly extends its cash runway, essential for ongoing clinical development. (Timing: The impact of this capital raise is immediate, providing financial stability and supporting development over the next 12-18 months.)

The successful pricing and expected closing of the $150 million underwritten public offering. (Timing: Expected to close on or about April 20, 2026.)

The successful completion of this underwritten public offering will secure $150M-$172.5M, crucially funding the ongoing Haduvio clinical trials. This directly addresses near-term cash burn concerns and allows the company to progress its pivotal Phase 3 program. (Timing: The offering is expected to close in the near future, providing funds for clinical development over the next several quarters.)

Successful FDA End-of-Phase 2 meeting and planned initiation of two pivotal Phase 3 trials for Haduvio in IPF-related chronic cough (Q2 and H2 2026), alongside other Phase 2b trials. The extended cash runway into 2028 is a critical financial de-risker. (Timing: Q2 2026 and H2 2026 for trial initiations; cash runway confirmed into 2028.)